Literature DB >> 15800933

Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer.

Volkan Ozenci1, Ashley M Miller, Andreas Palmborg, Lars Egevad, Georg A Jaremko, Karl Mikael Kälkner, Pavel Pisa.   

Abstract

BACKGROUND: In the present study, we had the rare opportunity to study immunological responses of TAL from ascites fluid in a patient with hormone-refractory prostate cancer.
METHODS: We evaluated tumor antigen-specific T-cell responses, induced by either prostate specific antigen (PSA) pulsed dendritic cells (DCs) or PSA peptides, in TAL and peripheral blood lymphocytes.
RESULTS: DC stimulation with PSA protein induced recognition of naturally processed PSA epitopes by both blood and ascites T cells. In contrast, only ascites T cells recognized the PSA-3 peptide, after stimulation with PSA-pulsed DCs or peptides. Finally, although IFNgamma secreting T cells were detectable in both blood and ascites by ELISPOT, multiplex cytokine assay detected the presence of predominantly Th2 cytokines.
CONCLUSIONS: Although tumor antigen-specific TAL were detected in ascites fluid, these cells were producing immunosuppressive cytokines which may contribute to tumor escape from recognition and/or destruction by the immune system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15800933     DOI: 10.1002/pros.20229

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  2 in total

1.  Oxidative dna damage of lymphocytes in peripheral blood and ascites in cancer patients.

Authors:  J Wang; S S Xing; S B Guo; W Jin; W Zhang
Journal:  Curr Oncol       Date:  2012-07       Impact factor: 3.677

2.  Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients.

Authors:  Weiwei Zhang; Kejun Liu; Bin Ye; Guolin Hu; Kelei Zhao; Yazhou Ren; Weijiang Liang
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.